Morgan Stanley & Co. Int'l plc Stabilisation Notice (5097B)

TIDMIRSH TIDMAZN

RNS Number : 5097B

Morgan Stanley & Co. Int'l plc

10 June 2021

Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful.

AstraZeneca PLC

Post-stabilisation Period Announcement

Further to the pre-stabilisation period announcement dated 26 May 2021, Morgan Stanley & Co. International plc as Coordinating Stabilisation Manager (contact: Morgan Stanley Debt Syndicate - Daniel Shane; telephone:+44 20 7677-7070) hereby gives notice that no stabilisation (within the meaning of Article 3.2(d) of the EU Market Abuse Regulation (596/2014),as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018) was undertaken by the Stabilisation Manager(s) named below in relation to the offer of the following securities.

 
 Issuer:                         AstraZeneca PLC 
 G ua ran tor (if any ):         N/A 
                                ----------------------------------- 
 ISIN:                           XS2347663507 
                                ----------------------------------- 
 A gg r egate nom inal amoun 
  t:                             EUR 800,000,000 
                                ----------------------------------- 
 D escr ipt ion:                 EUR 800,000,000 0.375 per cent. 
                                  Notes due 2029 
                                ----------------------------------- 
 Stab i l isation Manager(s):    Morgan Stanley & Co. International 
                                  plc 
                                  Goldman Sachs International 
                                  J.P. Morgan Securities plc 
                                ----------------------------------- 
 O ff er pr ice:                 99.584% 
                                -----------------------------------

This announcement is for information purposes only and does not constitute an invitation or offer to underwrite, subscribe for or otherwise acquire or dispose of any securities of the Issuer in any jurisdiction.

This announcement is not an offer of securities for sale into the United States. The securities referred to above have not been, and will not be, registered under the United States Securities Act of 1933 and may not be offered or sold in the United States absent registration or an exemption from registration. There has not been and will not be a public offer of the securities in the United States.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

STAFMMMTMTJBBBB

(END) Dow Jones Newswires

June 10, 2021 06:32 ET (10:32 GMT)

Astrazeneca (LSE:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024